Company Overview
Mainz Biomed N.V. operates within the healthcare sector, specifically focusing on diagnostics and research by developing and selling in-vitro diagnostic tests designed for the early detection of cancer in the United States and Europe. The company's core product portfolio includes ColoAlert, a colorectal cancer diagnostic molecular genetic stool test, and PancAlert, a stool-based screening test for the detection of pancreatic cancer. As a micro-cap entity, Mainz Biomed maintains a market capitalization of $10.56M and employs a workforce of 19 individuals to support its research and development initiatives. The annual revenue generated by the company stands at $659,935, a figure that underscores its position as a small-scale player with limited market penetration relative to established industry leaders.
Financial Health
The company reports a trailing twelve-month revenue of $659,935, yet this income is significantly offset by a net income of $-18,971,112 and an EBITDA of $-16,145,343, revealing a cost structure where expenses vastly exceed operational revenues. This substantial gap indicates that the company is burning through capital, likely due to high research and development costs associated with bringing new diagnostic tests to market. Free cash flow stands at $-8,186,486, which signifies a lack of financial flexibility and an ongoing reliance on external financing to sustain operations without generating internal liquidity. Despite the negative net income, the gross margin remains positive at 67.5%, suggesting that the cost of goods sold for its diagnostic tests is well-controlled relative to sales prices. However, the operating margin is reported at -2822.1% and the profit margin at 0.0%, highlighting severe inefficiencies in overhead management or significant one-time charges impacting profitability. The balance sheet shows a cash position of $1.91M against total debt of $3.09M, resulting in a debt-to-equity ratio of 122.65, which characterizes the capital structure as highly leveraged rather than conservative. Liquidity constraints are further evidenced by a current ratio of 0.52, indicating that the company possesses only 52 cents in current assets for every dollar of current liabilities it owes. Return on equity is listed as N/A due to the negative equity base, while return on assets stands at -114.4%, reflecting that the management of assets is currently destroying value rather than generating returns for shareholders.
Valuation Assessment
Valuation metrics present a complex picture where the trailing P/E ratio is N/A due to losses, while the forward P/E is listed as -1.14, implying that future earnings projections are also negative or that the market is pricing in significant downside risk. The price-to-book ratio is 1.37, indicating that the market values the company at a 37% premium over its book value, which is unusual for a loss-making firm and may reflect expectations of future asset appreciation or intangible value. Alternative valuation metrics such as the price-to-sales ratio of 16.01 and an EV/EBITDA of -0.27 suggest that investors are willing to pay a high multiple per dollar of revenue despite the lack of profitability, often seen in biotech firms betting on pipeline potential. The stock has experienced significant volatility, trading between a 52-week low of $0.55 and a 52-week high of $5.34, meaning the current price sits within a range that reflects substantial price discovery and market sentiment shifts. The beta value of 0.32 suggests that the stock exhibits low volatility relative to the broader market, moving less than 70% as much as the overall index in response to market movements.
Growth & Income
Revenue growth year-over-year has contracted by -44.9%, while earnings growth is N/A due to continued losses, indicating that the company is shrinking in terms of top-line sales while simultaneously facing financial headwinds. Because the company reports no dividend yield and a payout ratio of 0.0%, it does not distribute earnings to shareholders, which is consistent with a non-dividend payer strategy that reinvests all available capital, albeit negative, into growth initiatives. The absence of dividend payments confirms that the company prioritizes retaining cash or raising capital to fund its diagnostic test development rather than providing immediate income to investors. Overall, the growth and income profile of Mainz Biomed is defined by declining revenue, negative earnings, and a complete absence of shareholder distributions, presenting a high-risk, high-volatility investment characteristic of early-stage diagnostic development firms.